C4 Therapeutics, Inc. (CCCC) — 8-K Filings

8-K Filings (20)

• 8-K Filing — Apr 10, 2026
• C4 Therapeutics Files 8-K, Material Agreement Details — Apr 9, 2026 Risk: medium
  On April 9, 2026, C4 Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing includes exhibits such as a corporate deck, in
• C4 Therapeutics Files 8-K: Material Agreement & Exhibits — Oct 16, 2025 Risk: medium
  On October 16, 2025, C4 Therapeutics, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statem
• C4 Therapeutics Files 8-K: Other Events Reported — Oct 16, 2025 Risk: medium
  C4 Therapeutics, Inc. filed an 8-K on October 16, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events,
• C4 Therapeutics Files 8-K — Oct 1, 2025 Risk: low
  C4 Therapeutics, Inc. filed an 8-K on October 1, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other E
• C4 Therapeutics Files 8-K on Sept 22 — Sep 22, 2025 Risk: low
  C4 Therapeutics, Inc. filed an 8-K on September 22, 2025, reporting on events that occurred on September 20, 2025. The filing includes information related to Re
• C4 Therapeutics Files 8-K on Corporate Governance — Jun 18, 2025 Risk: low
  On June 18, 2025, C4 Therapeutics, Inc. filed an 8-K report. The filing primarily concerns amendments to its articles of incorporation or bylaws, submission of
• C4 Therapeutics Appoints New Chief Medical Officer — Apr 14, 2025 Risk: low
  C4 Therapeutics, Inc. announced on April 14, 2025, that its Board of Directors appointed Dr. Adam R. Schlegel as Chief Medical Officer, effective April 10, 2025
• C4 Therapeutics Files 8-K on Operations and Finance — Jan 14, 2025 Risk: low
  C4 Therapeutics, Inc. filed an 8-K on January 14, 2025, reporting on its results of operations and financial condition, as well as a Regulation FD Disclosure. T
• C4 Therapeutics Files 8-K — Dec 9, 2024 Risk: low
  C4 Therapeutics, Inc. filed an 8-K on December 9, 2024, reporting other events and financial statements. The filing does not contain specific financial figures
• C4 Therapeutics Appoints New Chief Medical Officer — Nov 20, 2024 Risk: medium
  C4 Therapeutics, Inc. announced on November 20, 2024, that Dr. Adam R. Schlegel has been appointed as Chief Medical Officer, effective November 19, 2024. Dr. Sc
• C4 Therapeutics Announces Board and Executive Changes — Oct 15, 2024 Risk: medium
  C4 Therapeutics, Inc. announced on October 15, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure
• C4 Therapeutics Acquired by Biogen; New CMO Appointed — Oct 11, 2024 Risk: medium
  On October 7, 2024, C4 Therapeutics, Inc. announced the appointment of Dr. Adam R. Schlegel as Chief Medical Officer. Dr. Schlegel, who previously served as Sen
• C4 Therapeutics Names New CMO, CMO Departs — Sep 3, 2024 Risk: medium
  C4 Therapeutics, Inc. announced on September 3, 2024, that Dr. Adam R. Schlegel will depart as Chief Medical Officer effective August 29, 2024. The company also
• C4 Therapeutics Files 8-K on Security Holder Vote — Jun 21, 2024 Risk: low
  C4 Therapeutics, Inc. filed an 8-K on June 21, 2024, reporting on a matter submitted to a vote of its security holders. The filing indicates a meeting or vote o
• C4 Therapeutics Appoints New Chief Medical Officer — Jun 10, 2024 Risk: medium
  On June 7, 2024, C4 Therapeutics, Inc. announced the appointment of Dr. Adam R. Schlegel as Chief Medical Officer. Dr. Schlegel previously served as Senior Vice
• C4 Therapeutics Appoints New Chief Medical Officer — Mar 8, 2024 Risk: medium
  C4 Therapeutics, Inc. announced on March 8, 2024, that Dr. Adam R. Schomer has been appointed as Chief Medical Officer, effective March 7, 2024. Dr. Schomer pre
• C4 Therapeutics Files 8-K: Material Agreement & Financials — Mar 4, 2024 Risk: medium
  On March 4, 2024, C4 Therapeutics, Inc. announced a material definitive agreement. The company also disclosed information related to Regulation FD and filed fin
• C4 Therapeutics Files Routine 8-K for Disclosure Compliance — Jan 11, 2024
  C4 Therapeutics, Inc. filed an 8-K on January 11, 2024, to disclose general information, specifically regarding Regulation FD and Financial Statements and Exhib
• C4 Therapeutics Reports Exit/Disposal Activities, Reg FD Disclosure — Jan 9, 2024
  C4 Therapeutics, Inc. filed an 8-K on January 9, 2024, reporting an event that occurred on January 8, 2024, related to 'Cost Associated with Exit or Disposal Ac

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX